Samsung Bioepis Entrusts Teva with Sales of Two Biosimilars in US, Europe, and Canada
Fasenra and Ilaris Biosimilars
Development, Approval, and Manufacturing Handled by Samsung Bioepis
Pipeline Expanded to Nine Candidates
Teva Pharmaceutical Industries (hereafter "Teva"), a global pharmaceutical company, will market two biosimilar candidates for immune disease treatments currently being developed by Samsung Bioepis in the United States, Europe, and Canada.
The headquarters building of Samsung Bioepis in Songdo, Incheon. Samsung Bioepis
View original imageOn October 1, Samsung Bioepis announced that it has entered into a partnership agreement with Teva for the development and commercialization of biosimilar SB41, referencing Fasenra (ingredient: benralizumab), and biosimilar SB44, referencing Ilaris (ingredient: canakinumab). Under the agreement, Samsung Bioepis will be responsible for the development, regulatory approval, and manufacturing of both candidates, while Teva will handle sales in the United States, Europe, and Canada.
The two companies also agreed to expansion options, including broadening their partnership to additional territories and collaboration on the development of other biosimilars. Specific contractual terms and financial details have not been disclosed.
Samsung Bioepis and Teva have previously collaborated on two occasions. Last year, the two companies launched Epysqli (EPYSQLI), a rare disease treatment, in the United States, and recently entered into a sales partnership in Canada for Opuviz (OPUVIZ), an ophthalmology treatment.
Kim Kyung-Ah, CEO of Samsung Bioepis, stated, "Based on the successful outcomes of our partnership with Teva, we have decided to pursue collaboration on two new candidates. We will continue to strengthen our pipeline across a range of disease areas and expand the supply of biosimilars for patients and healthcare systems worldwide."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Currently, Samsung Bioepis markets 11 products globally. With the addition of SB41 and SB44 to its previously disclosed pipeline of seven biosimilars, the company's follow-up pipeline now consists of a total of nine candidates.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.